newsfilter
← Latest News
GlobeNewswire·

Cingulate Reports Second Quarter 2024 Financial Results and Provides Development Update on Major Milestones Achieved

FDA Clears Cingulate to File for Marketing Approval of CTx-1301 targeted in 1H 2025Licensing Activity Continues KANSAS CITY, Kan., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical